Autologous stem cell transplantation (ASCT) has enabled the use of high-dose alkylating agents either as a single agent or in combination with other cytotoxic agents and/or total body irradiation (TBI) for the treatment of @entity1582 . Despite improved complete remission rates, relapse and regimen-related @entity137 remain challenging. In an effort to increase event-free survival and decrease the high incidence of regimen-related @entity137 , we have studied the use of @entity2879 in combination with reduced-dose @entity1863 and @entity786 as a conditioning regimen for ASCT in a group of 26 @entity1 with advanced @entity1582 . Median follow-up for the group was 30 months. There was no early treatment-related mortality. The main @entity137 was @entity33 . Otherwise, there was 1 case of reversible, clinically diagnosed @entity5501 . Post-engraftment, 10 @entity1 (38%) achieved CR, 15 (58%) @entity1 achieved PR or SD, and 1 @entity1 developed @entity74 (4%). Five @entity1 in PR and 1 with @entity74 before transplant attained a CR post-transplant. The median times for event-free survival and overall survival after transplantation were 24 and 43 months, respectively. In conclusion, conditioning with @entity1863 , @entity786 , and @entity2879 followed by ASCT is a safe regimen with comparable effectiveness to other previously used preparative regimens, thus providing another approach of non-TBI containing high-dose chemotherapy for @entity1 with @entity1582 .

@entity1863 , @entity786 , and @entity2879 as conditioning for autologous stem cell transplantation in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma'] @entity74 :: ('MESH:D030342', 'Disease') :: ['progressive disease'] @entity5501 :: ('MESH:D006504', 'Disease') :: ['hepatic veno-occlusive disease'] @entity1863 :: ('MESH:D002066', 'Chemical') :: ['busulfan']
@entity1582 :: (MESH:D009101,Disease) :: ['multiple myeloma']
